rSIFN-co / Sichuan Huiyang Life Sci - LARVOL DELTA

Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=7 | Terminated | Sponsor: Sichuan Huiyang Life Science and Technology Corporation | N=36 ➔ 7 | Trial completion date: Dec 2027 ➔ Nov 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Nov 2024; Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Endocrine Cancer • Lung Cancer • Melanoma • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Solid Tumor

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 (clinicaltrials.gov) - P2 | N=188 | Completed | Sponsor: Sichuan Huiyang Life Science and Technology Corporation | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Sichuan Huiyang Life Science and Technology Corporation | Trial completion date: Jun 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2026

Metastases • Trial completion date • Trial primary completion date • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Solid Tumor

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 (clinicaltrials.gov) - P2 | N=188 | Active, not recruiting | Sponsor: Sichuan Huiyang Life Science and Technology Corporation | Trial completion date: Jul 2024 ➔ Dec 2024

Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Sichuan Huiyang Life Science and Technology Corporation

Metastases • Trial completion date • Trial primary completion date • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Solid Tumor

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 (clinicaltrials.gov) - P2 | N=188 | Active, not recruiting | Sponsor: Sichuan Huiyang Life Science and Technology Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2023 ➔ Jul 2024

Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Sichuan Huiyang Life Science and Technology Corporation

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Sichuan Huiyang Life Science and Technology Corporation | Trial completion date: Dec 2022 ➔ Jun 2024 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Trial completion date • Trial primary completion date • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Solid Tumor

A phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours (ESMO 2019) - P1; "The RP2D of rSIFN-co was 30ug (1.6 × 10 7 IU) 3x/week for 21days followed by 7 days’ rest. Anti-tumour activity seen in heavily pre-treated advanced solid tumor patients. especially in HCC."

Clinical • P1 data

Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=36; Active, not recruiting; Sponsor: Sichuan Huiyang Life Science and Technology Corporation; Trial completion date: Dec 2021 ➔ Dec 2022

Clinical • Trial completion date • Colorectal Cancer • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Solid Tumor

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. (PubMed, Ann Med) - "rSIFN-co therapy alone or combined with other antiviral therapy is worth to be further studied.Key messagesThere are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. Interferon alphas, by inducing both innate and adaptive immune responses, have shown clinical efficacy in treating severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus.In this multicenter, head-to-head, randomized, clinical trial which included 94 participants with moderate-to-severe COVID-19, the rSIFN-co plus antiviral agents (lopinavir-ritonavir or umifenovir) was associated with a shorter time of clinical improvement than interferon-alpha plus antiviral agents."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=36; Active, not recruiting; Sponsor: Sichuan Huiyang Life Science and Technology Corporation; Trial completion date: Mar 2019 ➔ Dec 2021; Trial primary completion date: Feb 2019 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date

rSIFN-01: A Study of rSIFN-co in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=42; Completed; Sponsor: Sichuan Huiyang Life Science and Technology Corporation; Recruiting ➔ Completed

Clinical • Trial completion